23 June 2020
EHA 2020 Congress - Aggressive lymphoma updates
Aggressive lymphoma updates
Association (EHA) congress
Dr Michael Dickinson,
Consultant Haematologist. Disease group lead for
aggressive lymphoma, Peter MacCallum Cancer Centre
& Royal Melbourne Hospital
Dr Michael Dickinson spoke with
Donna Gairns, National Nurse Director of Lymphoma Australia about the key
abstracts for aggressive lymphomas that were presented during the EHA
congress in June 2020.
Dr Dickinson spoke about emerging group of therapies that are called bispecific monoclonal antibodies
and how they work. This leads to the
discussion around the presentation of the clinical trial that he is leading at
Peter MacCallum Cancer Centre and that was presented at the meeting during the
aggressive lymphomas: cellular and bispecific antibody therapies.
Dr Dickinson also provided an update
on CAR T-cells in Australia as of June 2020.
CD20-TCB in relapsed or
refractory non-Hodgkin lymphoma: durable complete responses and manageable
safety observed at clinically relevant doses in phase I dose escalation.
Other presentations and topics
discussed through the interview:
Phase I Alexander study of AUTO3 – first bicistronic
chimeric antigen receptor (CAR) targeting CD19 and CD22 with pembrolizumab in
patients with relapsed or refractory diffuse large B-cell lymphoma.
Phase 3, randomised, open-label
study of pembrolizumab (Pembro) versus brentuximab vedotin (BV) for treatment
of relapsed or refractory classical Hodgkin lymphoma (R/R): KEYNOTE-204
guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma:
final results of the international, randomised phase III HD17 by the GHSG.
For questions or comments, please contact Donna Gairns, National Nurse Director on 1800 953 081 or email email@example.com